Brian Abrahams

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS) over its Eylea patent. While the performance of the company’s Dupixent treatment is likely to be strong in the near term, chronic obstructive pulmonary disease (COPD) is likely to...

Shares of Neumora Therapeutics Inc (NASDAQ: NMRA) were trading lower on Tuesday, a month after the company announced its IPO on the NASDAQ exchange. RBC Capital Markets On Neumora Therapeutics Analyst Brian Abrahams initiated coverage with an Outperform rating and price target of $24. Neumora...

Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program. A proprietary physician survey indicates the rising appetite for novel JAK inhibitors (which could compete with Jakafi) could be higher than earlier...

Shares of Biogen Inc (NASDAQ: BIIB) were flying on Wednesday, after the biopharma company said its experimental Alzheimer’s drug with Japanese partner Eisai showed promising results. RBC Capital Markets On Biogen Analyst Brian Abrahams maintained an Outperform rating, while raising the price...

Biogen Inc (NASDAQ: BIIB) shares are now trading notably off their all-time high of $468.55 hit on June 7, achieved on the back of Aduhelm approval. An analyst at RBC Capital Markets has now turned bullish on the stock after remaining on the sidelines for too long. The Biogen Analyst: Brian...

The weekend was abuzz with rumors of U.K. pharma giant AstraZeneca plc's (NYSE: AZN) reported interest in U.S.-based large-cap biopharma Gilead Sciences, Inc. (NASDAQ: GILD). The report polarized investors and the sell-side alike as they debated the pros and cons of a potential combination. A...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

Shares of mid-cap biotech SAGE Therapeutics Inc (NASDAQ: SAGE), which focuses on therapies for central nervous system disorders, were trading higher Wednesday. What Happened Sage said the FDA approved its Zulresso — chemically brexanolone — an injection for...

Following the 90-percent year-to-date appreciation in Intercept Pharmaceutical, Inc. (NASDAQ: ICPT) shares, RBC Capital Markets considers the stock's risk-reward to be balanced.  The Analyst RBC Capital Markets analyst Brian Abrahams downgraded Intercept from Outperform to Sector...

As Tesla Inc (NASDAQ: TSLA) explores an exit from the public markets, one Street analyst on Wednesday said Celgene Corporation (NASDAQ: CELG) could pursue a similar path. The Rating RBC Capital analyst Brian Abrahams maintained an Outperform rating on Celgene with a $110 price target. The Thesis...

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. Here's how some Street analysts reacted to the news.  The Analysts Raymond James' Laura Chico maintained a Market...

Incyte Corporation (NASDAQ: INCY) has suffered a series of setbacks in its clinical programs, with the company's epacadostat  failing to meet endpoints in a late-stage study for metastatic melanoma when evaluated in combination with Merck & Co., Inc. (NYSE: MRK)'s...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) reported some encouraging results from the first three patients treated with the company’s microdystrophin gene therapy program for Duchenne Muscular Dystrophy (DMD), sending the stock soaring higher by 40 percent Tuesday and prompting positive...

After Proteostasis Therapeutics Inc (NASDAQ: PTI)’s mixed Phase 2 results from a study of its PTI-801 cystic fibrosis transmembrane conductance regulator, RBC Capital Markets said more data is necessary to de-risk the asset. The Analyst Analyst Brian Abrahams downgraded PTI from...

RBC Capital Markets said in a Thursday note it believes SAGE Therapeutics Inc (NASDAQ: SAGE) can still emerge from near-term catalysts as a mid-cap neuro leader. Accordingly, the firm initiated coverage of Sage Therapeutics at Outperform, with a $117 price target. At time of writing, shares were...